Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H8Cl3N3O4S2 |
Molecular Weight | 380.656 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(C=C(C(=C1)C(Cl)=C(Cl)Cl)S(N)(=O)=O)S(N)(=O)=O
InChI
InChIKey=QOVTVIYTBRHADL-UHFFFAOYSA-N
InChI=1S/C8H8Cl3N3O4S2/c9-7(8(10)11)3-1-4(12)6(20(14,17)18)2-5(3)19(13,15)16/h1-2H,12H2,(H2,13,15,16)(H2,14,17,18)
Molecular Formula | C8H8Cl3N3O4S2 |
Molecular Weight | 380.656 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clorsulon is a compound belonging to the benzenesulphonamide family. It is used in veterinary medicine for the treatment of liver fluke (monotherapy), gasrtointestinal and lung worms, lice, grubs and mites (in combination with ivermectin) in cattles. Clorsulon inhibits the enzymes involved in the glycolytic pathways of the common liver fluke (Fasciola hepatica or Fasciola gigantica), namely phosphoglycerate kinase and phosphoglyceromutase.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Fasciola phosphoglycerate kinase Sources: https://www.ncbi.nlm.nih.gov/pubmed/7088033 |
0.29 mM [Ki] | ||
Target ID: Fasciola phosphoglyceromutase Sources: https://www.ncbi.nlm.nih.gov/pubmed/7088033 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CURATREM Approved UseFor the treatment of immature and adult liver fluke (Fasciola hepatica) infestations in cattle. Launch Date9.8997122E11 |
|||
Curative | IVOMEC Approved UseIt is used for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctate, C. pectinate, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparous); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparous and O. radiatum for 28 days after treatment and O. ostertagi, T. axei and C. punctate for 21 days after treatment, and H. placei and C. oncophora, for 14 days after treatment. Launch Date6.0644157E11 |
|||
Curative | IVOMEC Approved UseIt is used for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctate, C. pectinate, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparous); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparous and O. radiatum for 28 days after treatment and O. ostertagi, T. axei and C. punctate for 21 days after treatment, and H. placei and C. oncophora, for 14 days after treatment. Launch Date6.0644157E11 |
|||
Curative | IVOMEC Approved UseIt is used for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctate, C. pectinate, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparous); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparous and O. radiatum for 28 days after treatment and O. ostertagi, T. axei and C. punctate for 21 days after treatment, and H. placei and C. oncophora, for 14 days after treatment. Launch Date6.0644157E11 |
|||
Curative | IVOMEC Approved UseIt is used for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctate, C. pectinate, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparous); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparous and O. radiatum for 28 days after treatment and O. ostertagi, T. axei and C. punctate for 21 days after treatment, and H. placei and C. oncophora, for 14 days after treatment. Launch Date6.0644157E11 |
|||
Curative | IVOMEC Approved UseIt is used for the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctate, C. pectinate, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparous); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis). It is also used to control infections of D. viviparous and O. radiatum for 28 days after treatment and O. ostertagi, T. axei and C. punctate for 21 days after treatment, and H. placei and C. oncophora, for 14 days after treatment. Launch Date6.0644157E11 |
PubMed
Title | Date | PubMed |
---|---|---|
The effect of ivomec super on dogs experimentally infested with Sarcoptes scabiei isolated from a patient. | 2001 Apr |
|
Ivermectin and clorsulon (ivomec super) in treatment of goats naturally infested with scab mites and biting lice. | 2001 Aug |
|
Efficacy of combined chemotherapy against gastrointestinal nematodes and Fasciola hepatica in cattle. | 2001 Aug 20 |
|
Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. | 2001 Jun 9 |
|
Effects of parenteral administration of doramectin or a combination of ivermectin and clorsulon on control of gastrointestinal nematode and liver fluke infections and on growth performance in cattle. | 2001 May 1 |
|
Effect of gastrointestinal nematode and liver fluke infections on weight gain and reproductive performance of beef heifers. | 2002 Aug 2 |
|
Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes. | 2003 Oct |
|
Field trial on the efficacy of an experimental fasciolicide compared with some commercial compounds in naturally infected cattle. | 2003 Sep |
|
Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo drug treatment with clorsulon. | 2004 Feb |
|
Ultrastructural observations on oral ingestion and trans-tegumental uptake of clorsulon by the liver fluke, Fasciola hepatica. | 2005 Feb |
|
A scanning electron microscope study on the route of entry of clorsulon into the liver fluke, Fasciola hepatica. | 2005 Jan |
|
Field trial on comparative efficacy of four fasciolicides against natural liver fluke infection in cattle. | 2006 Feb 18 |
|
Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. | 2006 Oct |
|
The efficacy of antihelminthic compound; Clorsulon against experimental Schistosoma mansoni infection. | 2007 Apr |
|
Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke. | 2007 Apr |
|
Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing. | 2008 Spring |
|
Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle. | 2009 Jun 10 |
|
Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells. | 2010 Aug 5 |
|
Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. | 2010 Feb 3 |
Patents
Sample Use Guides
Bovine liver fluke: one-quarter fluid ounce per 200 pounds of body weight (7 milligrams per kilogram or 3.2 milligrams per pound of body weight). 200 mcg ivermectin and 2 mg/kg body weight (1 mL/110 lb body weight). Bovine astrointestinal nematodes, lungworms, liver flukes, grubs, lice, and mites: 1 milliliter (10 milligrams of ivermectin and 100 milligrams of clorsulon) per 50 kilograms (110 pounds) as subcutaneous injection.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:12:32 UTC 2023
by
admin
on
Fri Dec 15 15:12:32 UTC 2023
|
Record UNII |
EG1ZDO6LRD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.1193
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
||
|
CFR |
21 CFR 520.462
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
||
|
CFR |
21 CFR 556.163
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB06767MIG
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
EG1ZDO6LRD
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
28303
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
C015675
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
DB11389
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
T-6
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL1474129
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
100000084011
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
m3665
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
262-100-2
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
758901
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
1140702
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
60200-06-8
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
43231
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
EG1ZDO6LRD
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
5237
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
C75213
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY | |||
|
DTXSID8045488
Created by
admin on Fri Dec 15 15:12:32 UTC 2023 , Edited by admin on Fri Dec 15 15:12:32 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |